| |
Partnership for IMS and IntrinsiQ
IMS Health has announced a multi-year alliance with oncology information provider IntrinsiQ Research. IMS gains an exclusive license to incorporate IntrinsiQ's US-based anonymized patient-level information with its own IMS Oncology Analyzer™ to create one of the largest oncology information sources.
IMS's market intelligence and consulting coverage for cancer treatment insights now span the U.S., Japan, Germany, France, U.K., Italy, and Spain. Its own core information includes anonymized patient level data and global sales and prescription figures.
IntrinsiQ's database gives clinically rich information captured at the point of care, with data on 80 tumor types and more than 13,000 unique, anonymized patient records updated monthly via its IntelliDose™ clinical dosing software. More than five million administrations of drug therapy are included and 36 months of history are available for in-depth analysis.
Gilles Pajot, Executive Vice President of IMS Health, says the firm's clients, 'including those in the biotech market, have a compelling need to better understand the various dimensions of clinicians' decisions for a line of therapy at various stages of cancer... This alliance is another step in IMS's strategy to broaden our oncology information assets and fuel consulting expertise to help our clients meet the challenges of this key market. This includes continuing to build our substantial expertise in health economics and outcomes research in 2006, particularly as it relates to oncology, to support pharma's need for proving the value of medicines.'
IMS Health had revenue of $1.8 billion in 2005 and is online at www.imshealth.com . IntrinsiQ's web site is at www.intrinsiq.com .
|
